Landiolol (also known as LDLL600 and ONO 1101) is a beta1 selective, ultra-short-acting β1-adrenergic blocker which is useful for managing supraventricular tachyarrhythmias in sepsis. The medication landiolol functions as an extremely short-acting, highly cardioselective beta blocker. It functions as an anti-arrhythmic medication. Landiolol reduces hemodynamic responses to bronchoscopy-assisted suctioning in intubated ICU patients.
Physicochemical Properties
| Molecular Formula | C25H40CLN3O8 |
| Molecular Weight | 546.0534 |
| Exact Mass | 545.25 |
| Elemental Analysis | C, 54.99; H, 7.38; Cl, 6.49; N, 7.70; O, 23.44 |
| CAS # | 144481-98-1 |
| Related CAS # | 144481-98-1 (HCl); 33242-30-5 |
| PubChem CID | 164457 |
| Appearance | White to off-white solid powder |
| Density | 1.201g/cm3 |
| Boiling Point | 727.5ºC at 760mmHg |
| Melting Point | 122-127ºC |
| Flash Point | 393.8ºC |
| Vapour Pressure | 3.24E-22mmHg at 25°C |
| LogP | 2.377 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 14 |
| Heavy Atom Count | 37 |
| Complexity | 666 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | Cl[H].O1[C@]([H])(C([H])([H])OC(C([H])([H])C([H])([H])C2C([H])=C([H])C(=C([H])C=2[H])OC([H])([H])[C@]([H])(C([H])([H])N([H])C([H])([H])C([H])([H])N([H])C(N2C([H])([H])C([H])([H])OC([H])([H])C2([H])[H])=O)O[H])=O)C([H])([H])OC1(C([H])([H])[H])C([H])([H])[H] |
| InChi Key | DLPGJHSONYLBKP-IKGOIYPNSA-N |
| InChi Code | InChI=1S/C25H39N3O8.ClH/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28;/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31);1H/t20-,22+;/m0./s1 |
| Chemical Name | [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate;hydrochloride |
| Synonyms | ONO1101; ONO-1101; ONO 1101 hydrochloride; LDLL600; LDLL 600; LDLL-600; Landiolol; Landiolol HCl; Landiolol hydrochloride |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | beta-adrenergic receptor |
| References |
[1]. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000 Aug;68(2):143-50. [2]. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med. 2015 Aug 4;4(3):251-7. |
| Additional Infomation |
Landiolol hydrochloride is a member of morpholines. See also: Landiolol (annotation moved to). Drug Indication Treatment of supraventricular arrhythmias |
Solubility Data
| Solubility (In Vitro) |
DMSO: 100~250 mg/mL (183.1~457.8 mM) Water: ~100 mg/mL Ethanol: ~42 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8313 mL | 9.1567 mL | 18.3133 mL | |
| 5 mM | 0.3663 mL | 1.8313 mL | 3.6627 mL | |
| 10 mM | 0.1831 mL | 0.9157 mL | 1.8313 mL |